Results 21 to 30 of about 181,087 (306)
Chimeric Antigen Receptor Therapy
New England Journal of Medicine, 2018 Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors.
Carl H. June, Michel Sadelain
openaire +3 more sources
Chimeric Antigen Receptor Therapy for Cancer [PDF]
Annual Review of Medicine, 2014 Improved outcomes for patients with cancer hinge on the development of new targeted therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical, and clinical arenas spanning cellular immunology, synthetic biology, and cell-processing technologies has paved the way for clinical applications of chimeric antigen receptor ...
David M, Barrett +4 more
openaire +2 more sources
Journal of Medical Case Reports, 2022 Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory ...
Bai-Yan Wang +20 more
doaj +1 more source
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
Global Manufacturing of CAR T Cell Therapy
Molecular Therapy: Methods & Clinical Development, 2017 Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor types.
Bruce L. Levine +3 more
doaj +1 more source
Nanobody based dual specific CARs [PDF]
, 2018 Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich +8 more
core +2 more sources
Chimeric antigen receptors that trigger phagocytosis [PDF]
eLife, 2018 AbstractChimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity, and suggests that applying CAR strategies to other immune cell lineages may be beneficial. Here, we engineered a family of Chimeric Antigen Receptors for Phagocytosis
Meghan A Morrissey +6 more
openaire +5 more sources
Chimeric antigen receptor–based therapies beyond cancer
European Journal of Immunology, 2023 Abstract Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology. This immunological breakthrough requires immune cell engineering with an artificial surface protein receptor for antigen‐specific recognition coupled to an ...
María Velasco‐de Andrés +6 more
openaire +3 more sources
Chimeric antigen receptor T cell
Indian Journal of Pharmacology, 2022 During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2/neu inhibitor, has been developed and accepted widely for management of chronic myeloid leukaemia and breast cancer ...
Singh, Surjit +4 more
openaire +2 more sources
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Frontiers in Immunology, 2018 Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant to conventional agents. Most notable are the remarkable responses seen in patients receiving autologous CD19-redirected chimeric antigen receptor (CAR) T cells for ...
Rohtesh S. Mehta, Katayoun Rezvani
doaj +1 more source